Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “EMBOLISM”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 217 records · Page 12Linked to original sources
PubMed2004

Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study.

BACKGROUND: Patients with atrial fibrillation (AF) have a higher mortality and risk of stroke/embolism than patients with sinus rhythm. HYPOTHESIS: The aim of the study was to assess the association of clinical and echocardiographic characteristics with mortality and stroke/embolism and the use of antithrombotic medication in the year 2000 in patients who participated 1990-1995 in the Embolism in Left Atrial Thrombi (ELAT) study. METHODS: The study included 409 outpatients with nonrheumatic AF (62 +/- 12 years, 36% women, 39% intermittent AF). Patients with thrombi received anticoagulation, patients without thrombi aspirin until follow-up in 1995; thereafter, anticoagulation according to clinical risk factors was recommended. Primary events were death and secondary events were stroke/embolism. All patients were contacted during the year 2000. RESULTS: Mean follow-up was 102 months. Mortality was 4%/year; the cause of death was cardiac (n = 84), fatal stroke (n = 26), malignancy (n = 23), sepsis (n = 5), and unknown (n = 24). Multivariate analysis identified age (p < 0.0001), heart failure (p = 0.0013), and reduced left ventricular systolic function (p = 0.0353) as predictors of mortality. Stroke/embolism occurred in 83 patients, with a rate of 3%/year. Multivariate analysis identified age (p = 0.0006) and previous stroke (p = 0.0454) as predictors of stroke/embolism. In the year 2000, 51 (21%) of the 247 surviving patients received no antithrombotic medication, 88 received (36%) oral anticoagulants, 102 (41%) acetylsalicylic acid, and 6 (2%) low-molecular heparin. CONCLUSIONS: Therapy for heart failure and oral anticoagulation in AF should be seriously considered, especially in elderly patients and in those with previous stroke.

Age Factors↗
PubMed1994

A study of embolizing materials for chemo-embolization therapy of hepatocellular carcinoma: effects of particle size and dose on chitin-containing cis-diamminedichloroplatinum(II) albumin microsphere antitumor activity in VX2 hepatic tumor model rabbits.

We prepared chitin-containing cis-diamminedichloroplatinum(II) (CDDP) albumin microspheres with various particle sizes, and investigated in vitro CDDP release; the antitumor effect towards VX2 tumor introduced into rabbits was then examined. It was found that the rate of release of CDDP from chitin-containing CDDP albumin microspheres in vitro was increased with reduced particle size. Administration of microspheres to VX2 tumor-bearing rabbits via the hepatic artery resulted in different profiles of plasma platinum concentration depending on the particle size, and a higher concentration of platinum was released from the beginning of administration as particle size was reduced. The platinum content in hepatic tissue following the administration of CDDP microspheres was increased as the particle size decreased, although the rate of increase was not uniform. The antitumor effect of CDDP assessed by the suppression of tumor growth tended to be higher when microspheres of smaller sizes were used. However, no significant difference was observed in tumor growth rate between rabbits injected with microspheres smaller than 20 microns and those injected with sizes between 20 and 37 microns (p > 0.05). We also examined the relationship between the CDDP dose and antitumor effect using microspheres of less than 20 microns and observed a dose-dependent antitumor effect. No significant difference was observed, however, between 2 and 4 mg eq CDDP/kg dose levels (p > 0.05). From these results, we concluded that microsphere size and CDDP dose were strongly correlated with the augmentation of antitumor effect of chitin-containing CDDP albumin microspheres used in chemo-embolization therapy via the hepatic artery.

Albumins↗
PubMed2000

[The development of embolizing materials for chemo-embolization therapy of hepatocellular carcinoma].

We developed chitin-containing cisplatin (CDDP) albumin microspheres (MS). We also investigated physical properties of MS in vitro, anti-tumor effect of MS in VX2 tumor model rabbits in vivo and clinical evaluation of MS. The CDDP contents, specific surface areas and yield of MS increased with an increase in the concentration of chitin. These findings suggest that accumulation of chitin on the surface of microsphere was the cause of expansion of the coated area as the concentration of chitin increased. In vitro CDDP releases decreased as the concentration of chitin increased. The initial burst effect of the drug was to be controlled by the increase of concentration of chitin. The chitin-containing CDDP microspheres showed similar CDDP release patterns irrespective of the concentration of chitin between 1 and 6 h after the administration of CDDP microspheres. After 6 h, the blood Pt levels increased with an increase in the concentration of CDDP microspheres suggesting a significant effect of the concentration of chitin on microsphere decomposability in vivo. Tumor growth rate was increasingly suppressed as the concentration of chitin increased. Clinical findings indicated that antitumor activity of chitin-containing CDDP albumin microspheres would have a chemoembolic effect by embolizing the hepatic artery. In the tumor and necrosis portions phagocytosis of microspheres by macrophage-like giant cell was shown. Consequently, the biocompatibility and decomposable properties of chitin-containing CDDP albumin microspheres were demonstrated.

Albumins↗
PubMed1997

Combination of transcatheter arterial embolization and percutaneous ethanol injection for hepatocellular carcinoma: comparison of efficacies of doxorubicin and epirubicin in transcatheter arterial embolization.

We administered a combination of transcatheter arterial embolization (TAE) and percutaneous ethanol injection (PEI) (ie, pretreatment with TAE and subsequent PEI) to treat 56 patients with multiple lesions (number of nodules < or = 3) or a single large (diameter > or = 3 cm) encapsulated lesion of hepatocellular carcinoma. The TAE included doxorubicin (40 mg) in 32 cases and epirubicin (mean, 82 mg) in the remaining 24 cases, and the efficacies of the two were compared. The therapeutic efficacy was evaluated on the basis of the survival rate and recurrence-free survival rate revealed by clinical follow-up. Both rates showed significant differences between the doxorubicin and epirubicin groups, with both being superior in the epirubicin group. It was surmised that epirubicin is a useful chemotherapeutic agent in TAE for patients with hepatocellular carcinoma.

Aged↗
PubMed1997

Zinostatin stimalamer-transcatheter arterial embolization for hepatocellular carcinoma: a comparison with lipiodol-transcatheter arterial embolization.

Twenty patients with unresectable hepatocellular carcinoma were treated by zinostatin stimalamer-transcatheter arterial embolization (SMANCS-TAE). After administration of SMANCS, a superselective catheterization technique was used to inject gelatin sponge particles into the artery or artery branch supplying the cancer-bearing segment. We compared the results of SMANCS-TAE with Lipiodol (Yamanouchi, Tokyo, Japan)-TAE performed during the same period. In 18 of 20 patients (90%), a tumor necrosis rate of 100% (grade 4) was obtained after one or two courses of SMANCS-TAE. The SMANCS group was superior to the Lipiodol-TAE group in terms of the tumor reduction rate, alpha-fetoprotein reduction rate, and cumulative 1.5-year survival rate, but not significantly. No severe side effects were noted after SMANCS-TAE. SMANCS-TAE appears to have potential as a new treatment for hepatocellularcarcinoma, and patients treated with this technique will be monitored to elucidate the long-term effects.

Aged↗
PubMed2005

Submassive pulmonary embolism and paradoxical embolic stroke treated with percutaneous rheolytic thrombectomy and closure of the patent foramen ovale.

The presence of patent foramen ovale (PFO) in patients with large pulmonary emboli (PE) is associated with an increased risk of stroke and mortality. Many patients are ineligible to receive thrombolytic therapy. We present a patient with bilateral PE and cryptogenic stroke who was treated effectively with rheolytic thrombectomy with AngioJet, PFO closure with CardioSeal device, and placement of an inferior vena cava filter.

Aged↗